A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

September 6, 2017

Primary Completion Date

May 5, 2020

Study Completion Date

September 24, 2029

Conditions
Hodgkin Disease
Interventions
DRUG

Brentuximab vedotin

Brentuximab vedotin infusion

DRUG

Doxorubicin

Doxorubicin infusion

DRUG

Vinblastine

Vinblastine infusion

DRUG

Dacarbazine

Dacarbazine infusion

Trial Locations (14)

165

Ospedale Pediatrico Bambino Gesu,UOC Onco-ematologia, Roma

10126

Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino

27100

Fondazione IRCCS Policlinico San Matteo, Pavia

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

50139

Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer, Florence

80045

Children's Hospital Colorado, Aurora

41253-190

Hospital Sao Rafael S/A, Salvador

81520-060

Jardim das Americas, Paranã

20230-230

INCA - Instituto Nacional de Cancer, Rio de Janeiro

04023-062

GRAACC - Grupo de Apoio ao Adolescente e a Crianca com Cancer, São Paulo

05403-000

ICr - Instituto da Crianca - HCFMUSP, São Paulo

08270-070

Hospital Santa Marcelina, São Paulo

460-0001

NHO Nagoya Medical Center, Nagoya

216-8511

St. Marianna University School of Medicine Hospital, Kawasaki-shi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY